Bit Digital (BTBT) – Second Quarter Results


Monday, August 18, 2025

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Transformation. Since the end of 1Q25, Bit Digital has transformed the business: first moving to an Ethereum treasury and staking platform, and then the WhiteFiber IPO. The focus going forward at Bit Digital is to build one of the largest institutional balance sheets in the public markets and generate scalable staking yield. We expect the WhiteFiber holding to be liquidated over time to fund this goal.

2Q25 Results. Revenue of $25.7 million fell from $29.0 million in 2Q24, was flat sequentially, and in-line with our $25.4 million estimate. The key difference was Mining revenue, which fell to $6.6 million from $16.1 million last year. Cloud Services revenue rose to $16.6 million from $12.5 million in 2Q24. Higher one-time G&A costs and lower gross margins across most business lines, offset by a $27.1 million gain on Digital Assets, resulted in operating income of $13.9 million, compared to an operating loss of $11.5 million in 2Q24, which was impacted by a $11.5 million loss on Digital Assets. The Company reported net income of $14.9 million, or $0.07/sh, versus a net loss of $12 million, or $0.09/sh last year. 


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Trump Signals Massive Semiconductor Tariffs as U.S. Expands Trade Duties

President Trump is preparing to roll out a new round of tariffs on semiconductor imports, signaling a sharp escalation in the United States’ trade strategy. The upcoming duties could reach levels as high as 300%, representing a major shift in the administration’s approach to key technology sectors. These tariffs are expected to be announced over the next couple of weeks and will likely have wide-ranging implications for the semiconductor industry and the broader economy.

This move continues a broader trend of imposing trade barriers across multiple sectors. Pharmaceutical imports are also expected to face similar duties in the near future, marking a significant expansion of tariffs beyond metals, machinery, and consumer goods. Economists anticipate that as these duties take hold, their effects will become more visible in economic indicators such as inflation and producer costs.

Early signs of tariff impact are already appearing in economic data. The wholesale price index showed a sharp rise in July, the fastest in roughly three years, suggesting that costs are increasingly being passed through to businesses. While the broader consumer inflation data has not yet reflected the full impact of previous tariffs, analysts expect that upcoming reports will more clearly show the consequences of higher import duties.

Despite concerns over inflation and trade disruptions, U.S. stock markets have so far remained resilient. Major indexes reached record highs recently, reflecting investor confidence and adaptation to the ongoing tariff environment. Revenue generated from existing tariffs has been substantial, though a portion of this revenue is indirectly borne by consumers through higher prices. The effect on corporate margins and consumer purchasing power is expected to intensify if new semiconductor and pharmaceutical duties are implemented at the highest proposed rates.

On the international front, trade negotiations continue to play a key role. An extension of the tariff truce with China has delayed further talks until November, temporarily easing tensions between the two largest economies. Current U.S. tariffs on Chinese imports average over 50%, creating a backdrop for the upcoming discussions with Canada, Mexico, and other trade partners. Reciprocal tariffs imposed on a range of countries earlier this month signal that Washington is aiming for a broader realignment of trade terms across multiple fronts.

Legal challenges to the tariffs remain unresolved. Multiple cases are currently pending in U.S. federal courts, including one high-profile appeal that could determine the legality of the administration’s tariff authority. A court ruling in either direction could significantly influence the trajectory of trade policy and investor sentiment.

As the U.S. government prepares to expand tariffs on semiconductors and pharmaceuticals, businesses and consumers alike are watching closely. The scale of the proposed duties represents one of the most aggressive trade actions in recent years, with potential ripple effects on global supply chains, technology production, and pricing. Economists, market analysts, and policymakers will be monitoring upcoming economic reports and legal developments to gauge how these tariffs will reshape the U.S. economy.

Xcel Brands (XELB) – Influencer Brands Set To Launch


Friday, August 15, 2025

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q2 Results. The company reported Q2 revenue of $1.3 million and an adj. EBITDA loss of $0.3 million, as illustrated in Figure #1 Q2 results. Importantly, while revenue was 22.3% lower than our estimate of $1.7 million, the adj. EBITDA loss of $0.3 million was largely in line with our expectations of a loss of $0.35 million. Furthermore, the on target adj. EBITDA figure was driven by the company’s strategic cost reduction and business transformation efforts, as well as the Lori Goldstein divestiture.

Favorable outlook. While the company is approaching the back half of the year with caution, largely driven by potential tariff impacts, we believe it stands to benefit from a number of favorable developments. Notably, the company is launching its Longaberger brand in Q3 on QVC and announced an accelerated timeline for its new influencer brands. Additionally, the company stands to benefit from its Halston brand as royalties kick in.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Unicycive Therapeutics (UNCY) – Actions Taken To Address Issues That Caused The CRL


Friday, August 15, 2025

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Actions Taken To Correct Manufacturing Findings. Unicycive reported a 2Q25 loss of $6.4 million or $(0.52) per share, with cash on June 30, 2025 of $22.3 million. Based on our current estimates, we believe this is sufficient to fund operations through 2H25. On June 30, the company received a CRL (Complete Response Letter) following an FDA inspection that found deficiencies at a contract manufacturer’s facility. The findings stopped the labeling discussions required for completion of the NDA review. The company has shifted to one of its other manufacturers, and filed a request for a meeting with the FDA. 

A Request For A Type A Meeting Was Filed. Following the receipt of the CRL, Unicycive filed a request for a Type A meeting with the FDA. This type of meeting is held to discuss the issues that led to the CRL and how to correct them. These meetings are usually scheduled within 30 days of the request. After meeting is held the company will receive the meeting minutes with requirements for resubmission of the NDA application. Unicycive expects to announce an updated plan for OCL development during 3Q25.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Euroseas (ESEA) – Second Quarter Financial Results Exceed Expectations; Increasing Estimates


Friday, August 15, 2025

Euroseas Ltd. was formed on May 5, 2005 under the laws of the Republic of the Marshall Islands to consolidate the ship owning interests of the Pittas family of Athens, Greece, which has been in the shipping business over the past 140 years. Euroseas trades on the NASDAQ Capital Market under the ticker ESEA. Euroseas operates in the container shipping market. Euroseas’ operations are managed by Eurobulk Ltd., an ISO 9001:2008 and ISO 14001:2004 certified affiliated ship management company, which is responsible for the day-to-day commercial and technical management and operations of the vessels. Euroseas employs its vessels on spot and period charters and through pool arrangements.

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Second quarter financial results. Total net revenues for the second quartertotaled $57.2 million, a 2.5% decrease year-over-year, but slightly higher than our estimate of $56.7 million. Adjusted EBITDA and EPS were $39.3 million and $4.20, respectively, above our estimates of $38.5 million and $3.87. The better-than-expected results were due to higher time charter equivalent (TCE) rates of $29,420 per day compared to our estimate of $28,502 per day, along with modestly lower-than-expected operating expenses of $23.9 million compared to our estimate of $24.7 million.

Market outlook. TCE rates for feeder vessels increased 8% in the second quarter due to limited vessel availability and robust demand. While the global containership orderbook remains high, the feeder and intermediate segments have a much smaller pipeline of just 4 to 8%, offering some insulation from the potential negative impact of an oversupplied market. Ongoing Red Sea conflicts have further supported rates by prompting Suez Canal re-routings and increasing distance. Although U.S. trade policies cloud visibility, we expect TCE rates to remain strong through year-end 2025 and into 2026.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

DLH Holdings (DLHC) – Ongoing Work with NIH


Friday, August 15, 2025

DLH delivers improved health and readiness solutions for federal programs through research, development, and innovative care processes. The Company’s experts in public health, performance evaluation, and health operations solve the complex problems faced by civilian and military customers alike, leveraging digital transformation, artificial intelligence, advanced analytics, cloud-based applications, telehealth systems, and more. With over 2,300 employees dedicated to the idea that “Your Mission is Our Passion,” DLH brings a unique combination of government sector experience, proven methodology, and unwavering commitment to public health to improve the lives of millions. For more information, visit www.DLHcorp.com.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Task Order. DLH has been awarded a task order valued at up to $46.9 million to continue providing information technology services, including enterprise IT systems management, cyber security, software development, cloud computing, and more, to the National Institutes of Health’s Office of Information Technology (“OIT”).

Details. The task order includes a base period and multiple options aggregating to a three-year period of performance. Through this award, DLH will leverage a comprehensive suite of digital transformation and cyber security solutions to support approximately 7,000 end-customers. As part of this new effort, DLH will design and implement a cloud migration strategy built on partnerships with leading commercial CSP vendors, including Azure, AWS, and Google.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

CoreCivic, Inc. (CXW) – Another New Contract


Friday, August 15, 2025

CoreCivic is a diversified, government-solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. We provide a broad range of solutions to government partners that serve the public good through high-quality corrections and detention management, a network of residential and non-residential alternatives to incarceration to help address America’s recidivism crisis, and government real estate solutions. We are the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and believe we are the largest private owner of real estate used by government agencies in the United States. We have been a flexible and dependable partner for government for nearly 40 years. Our employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. Learn more at www.corecivic.com.

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

West Tennessee. As anticipated, CoreCivic announced another new contract with U.S. Immigration and Customs Enforcement (ICE). Through an intergovernmental services agreement (IGSA) between the City of Mason, Tennessee, and ICE, CoreCivic will resume operations at the Company’s 600-bed West Tennessee Detention Facility, a facility that has been idle since September 2021.

Details. The IGSA expires in August 2030 and may be further extended through bilateral modification. The agreement provides for a fixed monthly payment plus an incremental per diem payment based on detainee populations. Total annual revenue once the facility is fully activated is expected to be approximately $30 million to $35 million, with margins consistent with the CoreCivic Safety segment.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Conduent (CNDT) – New Business Momentum Picking Up


Friday, August 15, 2025

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Solid Q2 results. Q2 revenue of $754 million aligned with our estimate, while adj. EBITDA of $37 million exceeded our forecast of $33 million. All three segments delivered sequential, new business, Annual Contract Value (ACV ) growth, a key forward indicator. This sales momentum supports our view that Conduent is on track to return to top-line growth in 2026.

Big Beautiful Bill may present upside. We view the recently passed “Big Beautiful Bill” as a potential tailwind for Conduent’s Government segment. The legislation tightens eligibility enforcement for public benefits, which may drive increased demand for outsourced eligibility verification and fraud detection, which are core capabilities for the company.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Cocrystal Pharma (COCP) – 2Q25 Reported With Norovirus and Influenza Product Updates


Friday, August 15, 2025

Cocrystal Pharma, Inc. is a clinical-stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication process of influenza viruses, coronaviruses (including SARS-CoV-2), hepatitis C viruses and noroviruses. Cocrystal employs unique structure-based technologies and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. For further information about Cocrystal, please visit www.cocrystalpharma.com.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Antivirals Continue To Move Forward. Cocrystal reported 2Q25 loss of $2.1 million or $(0.20) per share. During 2Q, the company presented data from its CDI-988 Phase 1 study in norovirus. Separately, CDI-988 has demonstrated inhibition of multiple strains, including GII.17 and GII.4 that have caused norovirus outbreaks over the past 2 years. The Phase 2a human challenge study testing CC-42344 in influenza has been extended. CC-42344 has shown inhibition of several strains of avian influenza that have caused public health concerns. Cash on June 30, 2025 was $4.8 million.

Phase 1b Is Planned For CDI-988  In Norovirus. Data from a Phase 1 trial showing safety and efficacy of CDI-988 was presented in August. The data show that CDI-988 was safe and effective through a range of doses in a single-ascending (SAD) and multiple-ascending (MAD) dose cohorts. A Phase 1b study testing CDI-988 as both treatment and prophylaxis for norovirus is planned for later in FY2025.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Strong September Corporate Bond Issuance Expected Despite Rate Cut Uncertainty

The U.S. corporate bond market is gearing up for a strong September, with investment-grade issuance expected to remain one of the highest of the year. Market strategists and bankers anticipate that companies will proceed with large volumes of bond sales despite a shift in expectations for Federal Reserve interest rate cuts.

Historically, September has been one of the busiest months for investment-grade corporate bond activity, averaging around $140 billion in new deals. Last year set a record, surpassing $172 billion, as companies took advantage of robust investor demand for higher-yielding assets. This year’s issuance is projected to be similarly active, driven primarily by corporate financing needs rather than short-term changes in interest rate forecasts.

Recent economic data has tempered expectations for a substantial Fed rate cut in the near term. Producer price growth accelerated, while consumer price increases aligned with forecasts, suggesting inflation remains stubborn. As a result, markets now anticipate smaller or delayed rate adjustments compared to earlier projections.

Despite the evolving interest rate outlook, corporate treasurers are unlikely to postpone planned September bond offerings. Issuance decisions are typically based on long-term funding strategies and capital requirements, not on the immediate direction of monetary policy. Analysts note that minor movements in yields or credit spreads rarely deter companies from moving forward during this historically active month.

Corporate credit spreads—the additional yield investors demand over U.S. Treasuries—have experienced only modest changes in recent weeks. On average, spreads tightened by about one basis point, leaving them close to multi-decade lows. Bond yields remain below January levels, maintaining favorable financing conditions for issuers.

Industry experts expect that the two weeks leading up to Labor Day will be relatively quiet, as is common, but issuance is likely to accelerate sharply in September. With annual investment-grade supply in the U.S. often approaching $1.5 trillion, market participants anticipate continued heavy calendars in late summer and early fall.

The upcoming wave of bond sales will also be influenced by broader market dynamics, including investor appetite for corporate debt and the ongoing search for yield in a still-uncertain interest rate environment. Many institutional investors view investment-grade corporate bonds as an attractive balance between risk and return, especially when economic data signals resilience in corporate earnings and credit quality.

Overall, the combination of strong historical precedent, stable credit conditions, and ongoing financing needs suggests that September will remain a peak month for U.S. corporate bond issuance. Whether or not the Fed adjusts rates in the near term, companies are expected to press forward, ensuring the corporate bond market stays active as the year heads into its final quarter.

Producer Prices Jump Most in 3 Years: Complicates Fed’s Rate Cut Timeline

The Federal Reserve’s carefully orchestrated path toward interest rate cuts hit an unexpected roadblock Thursday as producer price data revealed the most significant inflationary surge in over three years, casting doubt on the central bank’s timeline for monetary easing.

The Producer Price Index (PPI) jumped 0.9% in July, dramatically exceeding economists’ expectations of just 0.2% and marking the sharpest monthly increase since early 2022. This surge pushed annual producer inflation to 3.3%, the highest level since February and a stark reminder that the battle against rising prices remains far from over.

More concerning for policymakers was the performance of core producer prices, which strip out volatile food and energy costs to provide a clearer picture of underlying inflation trends. These prices rose 0.6% monthly, representing the largest increase since March 2022 and a significant acceleration from June’s flat reading. The annual core rate also hit 3.3%, matching February’s peak.

The timing of this inflation shock couldn’t be more problematic for the Federal Reserve. Just days after consumer price data showed inflation pressures remaining stubbornly above the Fed’s 2% target, producer prices have delivered another unwelcome surprise. Markets, which had priced in a virtual certainty of rate cuts beginning in September, are now recalibrating their expectations.

This producer price acceleration tells a troubling story about cost pressures flowing through the economy. Unlike consumer prices, which measure what households pay, producer prices capture the costs businesses face when purchasing goods and services. When these prices rise rapidly, companies face a critical decision: absorb the higher costs and accept reduced profit margins, or pass them along to consumers through higher retail prices.

Recent evidence suggests businesses are increasingly choosing the latter option. Economists point to growing margin pressures from tariffs on imported goods as a key driver behind this trend. Analysis from Nationwide indicates that while companies initially absorbed most tariff-related cost increases, margins are becoming increasingly strained by higher costs for imported goods, leading to expectations of stronger price pass-through to consumers in coming months.

The mechanics behind July’s surge reveal interesting dynamics within the economy. Analysis from Capital Economics highlighted an unusual increase in margins for wholesalers and retailers, suggesting that some of the price increases reflect strategic business decisions rather than pure cost pressures. This margin expansion indicates companies may be regaining pricing power after years of competitive pressure.

Financial markets reacted swiftly to the news, with stock indices declining as investors grappled with the implications for Federal Reserve policy. The probability of a September rate cut, which stood at 100% just Wednesday, dropped to approximately 95% following the release, while expectations for a larger 0.5% cut nearly evaporated entirely.

The producer price shock arrives at a particularly sensitive moment for Federal Reserve Chair Jerome Powell, who is scheduled to address the Jackson Hole Economic Symposium on August 22. This highly anticipated speech was expected to lay the groundwork for the Fed’s transition from restrictive monetary policy to a more accommodative stance. However, the recent inflation data complicates that narrative considerably.

For consumers already feeling the squeeze from elevated prices, the producer price surge offers little comfort. With businesses facing higher input costs and showing increased willingness to pass these expenses along, household budgets may face additional pressure in the months ahead. The disconnect between the Fed’s 2% inflation target and current price trends suggests that relief for American families remains elusive.

The path forward for monetary policy now appears more uncertain than at any point in recent months. While labor market softening and economic growth concerns continue to build the case for rate cuts, persistent inflation pressures argue for maintaining restrictive policies longer. Powell and his colleagues face the challenging task of balancing these competing forces while maintaining credibility in their inflation-fighting mission.

As markets await Powell’s Jackson Hole remarks, one thing has become clear: the Federal Reserve’s policy decisions will require careful calibration as conflicting economic signals continue to complicate the monetary policy landscape.

The Oncology Institute, Inc. (TOI) – Patient Additions And Pharmacy Division Drive 2Q25 Revenues Above Expectations


Thursday, August 14, 2025

TOI is an oncology practice management company that provides administrative services to oncology clinics. These clinics provide cancer care to a population of approximately 1.9 million patients. Services include cancer care, pharmacy and dispensary services, clinical trials, and services associated with oncology care. The company employs nearly 120 clinicians and over 700 teammates at over 70 clinic locations.

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Revenues Were Driven By New Patients Under Contract. The Oncology Institute reported a loss for 2Q25 of $17.0 million or $(0.15) per share. Revenues of $119.8 million exceeded our estimate of $110.4 million. The company discussed newly active or pending contracts that will add covered lives during 2H25. It reiterated its guidance for Revenues, Gross Profit, Adjusted EBITDA, and Free Cash Flow. Cash on June 30, 2025 was $30.3 million.

Patient Services Were Close To Our Expectations. The Patient Services division reached $55.9 million. New payor contracts added patients during 1H25 that began generating revenues, although they have a period of higher cost during the transition to TOI management. We expect the patient mix to include more continuing patients during 2H25, improving margins while new contracts continue to drive growth.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

SKYX Platforms (SKYX) – Revised Forecasts Reflect Phased Rollout, Long-Term Outlook Intact


Thursday, August 14, 2025

Patrick McCann, CFA, Research Analyst, Noble Capital Markets, Inc.

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Q2 results. SKYX reported Q2 revenue of $23.1 million, up 7.5% year over year and 14.7% sequentially. Gross margin expanded 190bps to 30.3%, supported by a favorable mix shift toward proprietary tech-embedded products. The adj. EBITDA loss of $2.6 million was slightly wider than our forecast of a $2.3 million loss but reflects underlying operating leverage as revenue scales.

Smart City partnership reinforces revenue growth trajectory. The company’s partnership with the $3 billion Smart City development in Miami’s Little River District positions it for sustained long-term growth. We expect the rollout to drive meaningful topline and branding impact over time, with strategic visibility among large-scale developers likely to reinforce future adoption of SKYX’s technology in both residential and commercial verticals.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.